lung metastasis. Some investigators have recently proposed that lung metastases from VEGF-C-overexpressing breast tumors could be secondary to lymph node metastases (8). This study does not support this hypothesis. The differential regulation of lymphogenic versus hematogenic metastases by VEGF-C and VEGF-D may be a function of the proteolytic processing of these molecules (5), which in turn may be governed by hosttumor interactions (6) .
Second, what is the clinical evidence to support the use of lymphatic markers to predict lymphatic metastasis? Both VEGF-C and VEGF-D are associated with increased lymphatic metastasis in some human tumors (6). However, there is a lack of correlation between lymphatic metastasis and the density of a variety of lymphatic markers for a number of human malignancies (Table 1) , including human lung cancer, which is the subject of this preclinical study by He et al. (7). Many animal studies including this one, show a positive association between the density of lymphatic markers and lymphatic metastasis (1, 3, 4, 7, 8) . Is this discordance between preclinical and clinical findings a result of the limitations of the animal models used or of the nonspecificity of current lymphatic markers? Is it possible that the markers available at present are unable to distinguish between functional and nonfunctional lymphatic vessels ( Fig. 1 ) (4), leading to these contradictory results? Lymphatic metastasis can occur in tumors that lack intratumor functional lymphatics, suggesting that functional lymphatics in the tumor margin are responsible for lymphatic dissemination (4). Therefore, microlymphangiography in patients coupled with lymphatic identification by molecular markers is needed to provide clearer insight into lymphatic metastasis in humans.
Third, how can antilymphangiogenic therapy be translated to the clinic? The work presented by He et al. (7), and that of Stacker et al.
(1), clearly shows that lymphatic metastasis can be prevented by anti-VEGF-C and anti-VEGF-D therapy given before the establishment of the primary tumor. However, by the time most tumors are detected clinically, they are already established, and metastatic cells may have already spread to the nearby lymph nodes or distant organs. Therefore, preclinical studies that initiate treatment after the primary tumor is established and lymphatic spread has occurred are now needed to build the basis for clinical trials of antilymphangiogenic therapy. Moreover, additional molecular players other than VEGF-C and VEGF-D may be involved in determining the clinical end points. After all, metastasis is a multistep process (29) in which cancer cells must detach from their neighbors, invade the surrounding extracellular matrix, enter the blood/lymphatic vessels, survive in the lumen, attach at a distant site, extravasate, migrate, proliferate, and recruit new vessels. It is likely that VEGF-C and VEGF-D are key players for some tumors and not for others. As the techniques for detection of various proteolytically processed forms of VEGF-C and VEGF-D become widely available, we may be able to preselect tumors that are VEGF-C or VEGF-D dependent and to design appropriate interventions. The future of cancer treatment may involve a combination of agents that block the different steps of metastasis and that are tailored to individual patients on the basis of their proteomic profile. The work by He et al. (7) is an important step in this direction. *EHC ‫ס‬ enzyme histochemistry; IHC ‫ס‬ immunohistochemistry; RPA ‫ס‬ RNA protection assay; RT-PCR ‫ס‬ reverse transcription-polymerase chain reaction; BVI ‫ס‬ blood-vessel invasion; DFS ‫ס‬ disease-free survival; ISR ‫ס‬ inflammatory stromal reaction; LI ‫ס‬ lymphatic invasion; LNM ‫ס‬ lymph node metastasis; OS ‫ס‬ overall survival; VEGFR-3 ‫ס‬ vascular endothelial growth factor receptor 3; LYVE-1 ‫ס‬ lymphatic vessel endothelial hyaluronan receptor 1.
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†The reduced presence of the long form of VEGFR-3 mRNA was associated with an increased incidence of lymph node metastases. ‡Podoplanin was used to identify lymphatic invasion. §VEGFR-3 staining was shown to be mostly blood vessels in the tumor. Association based on increased lymphatic vessel diameter. in red) , was used to trace the drainage patterns (28) of a MDA-MB-231 mammary carcinoma grown orthotopically. Although the lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE)-1 (black arrows) stained various structures within these tumors, ferritin was not present in these structures. Similar results were found within MDA-MB-435S mammary carcinomas. However, ferritin was found in LYVE-1-stained structures in the margin and normal tissue surrounding these tumors (data not shown). Scale bar ‫ס‬ 100 m.
